July 5, 2019
New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy. PARP inhibitors are molecular targeted cancer drugs used to treat women with ovarian cancer who have the BRCA1 and BRCA2 gene mutations. The drugs are showing promise in late-stage […]